Where does AGLE stock trade?

Aeglea BioTherapeutics Inc. (AGLE) is listed on NASDAQ.

What sector and industry is AGLE in?

Aeglea BioTherapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.

When did Aeglea BioTherapeutics Inc. go public?

Aeglea BioTherapeutics Inc. (AGLE) completed its IPO in 2016.

What companies are similar to AGLE?

Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare AGLE side-by-side with any of them on Quantisnow.

How can I track AGLE on Quantisnow?

Quantisnow aggregates Aeglea BioTherapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AGLE to receive live email and push alerts on every new disclosure.

AGLE

NASDAQ

Aeglea BioTherapeutics Inc.

SectorHealth CareIndustryBiotechnology: Pharmaceutical PreparationsIPO2016

$12.09+1.55 (+14.71%)

Follow Website

News25/Ratings0

Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria. In addition, the company's preclinical pipeline includes cystinuria and research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.

Latest news

25 items

AGLE FAQ

6 questions

What does Aeglea BioTherapeutics Inc. do?
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria. In addition, the company's preclinical pipeline includes cystinuria and research programs. The...
Where does AGLE stock trade?
Aeglea BioTherapeutics Inc. (AGLE) is listed on NASDAQ.
What sector and industry is AGLE in?
Aeglea BioTherapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.
When did Aeglea BioTherapeutics Inc. go public?
Aeglea BioTherapeutics Inc. (AGLE) completed its IPO in 2016.
What companies are similar to AGLE?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare AGLE side-by-side with any of them on Quantisnow.
How can I track AGLE on Quantisnow?
Quantisnow aggregates Aeglea BioTherapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AGLE to receive live email and push alerts on every new disclosure.